ATL77 Antibody

Overview of ATL77 Antibody

The ATL77 antibody is associated with T-cell receptor (TCR) clonal analysis in patients with chronic graft-versus-host disease (cGVHD) and related T-cell malignancies. It is linked to specific TCRβ rearrangements and somatic mutations observed in dominant T-cell clones, as identified through RNA sequencing studies .

TCRβ Rearrangement and Mutation

• TRBV4-2 Gene Rearrangement: ATL77 exhibits a unique TCRβ chain rearrangement involving the TRBV4-2 gene segment .

• Point Mutation: A critical somatic mutation at the 28th base pair (adenine → guanine) leads to an amino acid substitution (arginine → glycine) at position 10 of the CDR3 region .

Table 1: Key Genetic Characteristics of ATL77 Antibody

Role in Clonal T-Cell Expansion

• Clonal Dominance: ATL77 was identified as one of two dominant clones in a patient sample (ATL77), showcasing identical TCRβ rearrangements and mutations .

• Pathogenic Implications: Such mutations may contribute to aberrant T-cell activation, potentially driving autoimmune or lymphoproliferative disorders .

Comparative Analysis with Other ATL-Associated Antibodies

Table 2: ATL77 vs. Other ATL-Related Antibodies

Clinical and Diagnostic Relevance

• Biomarker Potential: The mutation in ATL77 could serve as a biomarker for tracking clonal T-cell populations in cGVHD or ATL .

• Therapeutic Targeting: Antibodies targeting mutant TCR regions, like ATL77, may offer avenues for immunotherapy in T-cell malignancies .

Limitations and Future Directions

• Functional Studies Required: The exact mechanism of ATL77’s role in disease pathogenesis remains uncharacterized.

• Broader Cohort Analysis: Validation in larger patient cohorts is needed to confirm its diagnostic utility .